Kodiak Sciences Q3 net loss $77M; cash $537M; Ph3 trials on track for 2023 readouts

Kodiak Sciences Inc.

2022-Q3 EPS reported -$5.04

Net loss of $77.0M ($1.47/sh) vs $67.5M ($1.30) in Q3 2021; increase driven by stock-based compensation.
Cash, cash equivalents and marketable securities of $537.4M; includes $2.5M unrealized loss from interest rates.
R&D expenses $61.7M (up from $56.0M) and G&A $17.8M (up from $11.5M) both primarily due to non-cash stock comp.
Four Phase 3 trials (GLEAM/GLIMMER DME, DAYLIGHT wet AMD, GLOW NPDR) expected to report topline data in 2023.
KSI-501 IND filing on track for Q4 2022; Phase 1 study expected to begin early 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Kodiak Sciences Inc. reported third quarter of 2022 results: net income $77.0 million, or $1.47 per share.

Period: third quarter of 2022
Net income: $77.0 million, or $1.47 per share
Result: reported results

Exact text from the filing

Kodiak Sciences Inc. (the “Company”) issued a press release reporting the Company’s financial results for the quarter ended September 30, 2022.

View on SEC.gov

Browse all earnings releases →

Kodiak Sciences Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-023842

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.